FDA Approves First-in-Class Factor VIII Therapy for Hemophilia A
February 24th 2023Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl; Sanofi] is high-sustained factor VIII replacement therapy indicated for routine prophylaxis and on-demand treatment to control bleeding episodes and for perioperative management in adults and children with hemophilia A.
Read More
FDA Accepts Biologics License Application for RSV Maternal Vaccine Candidate
February 23rd 2023If approved, the vaccine would be the first immunization for use in pregnant individuals to help protect against the complications of respiratory syncytial virus in infants from birth through 6 months.
Read More